(CercleFinance.com) – AstraZeneca announces total revenue of $12,679 million for the 1st quarter, up 17% compared to the same period a year earlier (or +19% at constant exchange rates ).
Pre-tax profit stood at $2,800 million, up 24% (+34% at constant exchange rates).
The Anglo-Swedish laboratory announces quarterly adjusted EPS of $1.41, up 21% (+30% at constant exchange rates) compared to the 1st quarter of 2023.
Core EPS stood at $2.06, up 7% (+13% at constant exchange rates).
Pascal Soriot, CEO of AstraZeneca, also highlights the positive and ‘unprecedented’ trial results obtained for Imfinzi and Tagrisso in lung cancer.
“We also look forward to seeing the results of several other important project trials throughout the year,” he added.
In this context, AstraZeneca will announce a 7% increase in the annual dividend at its Annual General Meeting.
For 2024, AstraZeneca confirms its objectives with total revenue and core EPS expected to increase in a range of approximately 10% to 14%.
Copyright (c) 2024 CercleFinance.com. All rights reserved.